Nixon Peabody Trust Co. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nixon Peabody Trust Co. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 398 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Nixon Peabody Trust Co.’s holdings in Regeneron Pharmaceuticals were worth $418,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quent Capital LLC grew its position in Regeneron Pharmaceuticals by 5.1% during the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 19 shares during the last quarter. Covestor Ltd grew its holdings in shares of Regeneron Pharmaceuticals by 7.4% during the 1st quarter. Covestor Ltd now owns 202 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 14 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in Regeneron Pharmaceuticals by 17.5% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 6,920 shares of the biopharmaceutical company’s stock worth $6,660,000 after purchasing an additional 1,030 shares during the period. UniSuper Management Pty Ltd raised its position in Regeneron Pharmaceuticals by 174.1% in the 1st quarter. UniSuper Management Pty Ltd now owns 2,409 shares of the biopharmaceutical company’s stock worth $2,319,000 after purchasing an additional 1,530 shares during the period. Finally, Capitolis Liquid Global Markets LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth $36,575,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on REGN. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.2 %

Regeneron Pharmaceuticals stock traded down $1.73 during trading hours on Monday, hitting $755.08. 47,191 shares of the stock traded hands, compared to its average volume of 528,290. Regeneron Pharmaceuticals, Inc. has a one year low of $750.20 and a one year high of $1,211.20. The firm’s 50-day moving average price is $985.21 and its two-hundred day moving average price is $1,034.89. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market cap of $82.98 billion, a PE ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.